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CONTEXT AND OBJECTIVE: Chronic use of ben-
zodiazepines is frequent in general practice. The 
aim of this study was to describe the usage pat-
tern and profi le of chronic users of diazepam who 
had been consuming this drug for a minimum of 
thirty-six months continuously.
DESIGN AND SETTING: This was a descriptive 
study (survey and clinical assessment) at fi ve pri-
mary healthcare centers in Campinas, Brazil.
METHODS: Psychotropic drug control books 
revealed 48 eligible patients. Among these, 41 
were assessed by means of the Schedule for 
Clinical Assessment in Neuropsychiatry (SCAN), 
the Hospital Anxiety and Depression scale (HAD) 
and a questionnaire on usage pattern.  
RESULTS: Most patients were women (85.4%). 
The patients’ mean age was 57.6 years, and 
they were from the social strata C (39%), D (54%) 
and E (7%). The mean length of diazepam con-
sumption was 10 years. The patients presented 
a lack of prescription compliance and had made 
frustrated attempts to stop using the drug. 55.5% 
said their doctor had never given any guidance 
on the effects of the drug. According to SCAN, 
25 patients (61%) suffered from depressive disor-
ders; only 12 cases of benzodiazepine depend-
ence were detected by this instrument. 
CONCLUSION: There is a need to improve the 
detection and treatment of mental disorders, as 
well as to prevent inappropriate prescription and 
use of benzodiazepines. Diazepam dependence 
has distinctive characteristics that make it unde-
tected by SCAN.   
KEY WORDS: Diazepam. Benzodiazepines. 
Anti-anxiety agents. Primary health care. Drug 
prescriptions.
INTRODUCTION
Benzodiazepines are drugs with an anxio-
lytic effect, based on chlordiazepoxide synthe-
sis, that started to be used in the 1960s. Their 
proven safety in comparison with barbiturates 
has contributed towards increased prescription 
rates since the 1970s.1,2 In the United States, 
10-15% of adults take benzodiazepines at 
some time over a 12-month period and 2% 
use them chronically.2 Studies conducted in 
Chile, Italy and Spain have revealed prevalence 
of use of between 4 and 7.5% over the past 12 
months.3-5 A fi gure of 10.2% has been found 
for the city of São Paulo, Brazil.6 A higher rate 
of 21.3% has been found in Porto Alegre, in 
southern Brazil.7 Besides high prevalence rates, 
studies have also indicated similarities in user 
profi le, such that they are especially used 
among women and the elderly.8-12 
One important matter to be considered 
regarding benzodiazepine consumption is 
physicians’ prescription habits, in addition 
to the usage pattern adopted by patients 
and their clinical profi le. Some problems 
such as cognitive loss even after interruption, 
tolerance development, withdrawal symp-
toms and dependence have been associated 
with the chronic use of benzodiazepines.13-17 
The problem becomes worse among the 
elderly because of age-related problems such 
as frequent comorbidities, use of several 
medications and pharmacodynamic as well 
as pharmacokinetic alterations.18-20 
OBJECTIVE 
The aim of this study was to describe the 
usage pattern for diazepam provided by phar-
macies at primary healthcare centers (PHCCs) 
and evaluate the profi le of users who had been 




This was a descriptive study in which 
chronic users of diazepam were surveyed 
and assessed by means of a standardized 
psychiatric instrument.
Setting and subjects
This study was conducted in the north-
eastern region of the city of Campinas (State of 
São Paulo) in 2001. This region had 152,438 
residents at that time (15.7% of the popula-
tion of the city), and was characterized by its 
poor economic status and high unemployment 
rates. It had eight PHCCs, four of which 
had a mental health team. Five PHCCs were 
included in this study because they were the 
fi rst to implement the use of psychotropic 
drug control books. These books revealed that 
1,458 individuals had received diazepam at 
some time over the past three years. 
The inclusion criteria for the present 
study were that the patients should be over 
15 years old and among these 1,458 indi-
viduals, who had been using diazepam for 
a minimum of thirty-six months continu-
ously, according to the monthly records in 
the books. These monthly records were, 
in turn, in accordance with the prescriptions 
made by the patients’ doctors. Further-
more, the patients had to confi rm that they 
were the users of the benzodiazepines 
provided to them by the PHCC pharmacy. 
Accordingly, 48 individuals were eligible 
(the other 1410 had not taken diazepam for 
a minimum of thirty-six months continu-
ously). It was possible to evaluate 41 of them 
(six patients did not respond to the three 
recall invitations made and one patient had 
moved to another town).
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Instruments and variables
The following data collected from the 
psychotropic drug control books were stored 
in an electronic fi le: total annual consumption 
of diazepam; average monthly consumption; 
mean duration of use; average daily dosage; 
and prescribing physician’s specialty.  
The clinical assessment of the patients involved:
1. A questionnaire to assess socioeconom-
ic status based on ownership of items 
and the reported educational level of the head 
of the family. This instrument included fi ve 
social strata, A to E, defi ned by score ranges.21 
These strata were in accordance with the 
defi nitions of the Instituto Brasileiro de 
Geografi a e Estatística (IBGE).
2. The Hospital Anxiety and Depression 
scale (HAD). This consisted of 14 multi-
ple choice questions within two subscales: 
depression and anxiety. The overall score 
for each subscale ranged from 0 to 21.22 
Patients whose score was more than eight 
in the respective HAD subscales were 
considered to be possible cases of anxiety 
and depression, in accordance with the 
national validation study.23 
3. The Schedule for Clinical Assessment in 
Neuropsychiatry (SCAN). This consisted 
of a sequence of tools that identifi ed, mea-
sured and classifi ed psychopathological 
conditions and also behavior associated 
with psychiatric disorders in adults.24 
Besides the formal psychiatric diagnosis, 
the second section of SCAN consisted 
of a list of physical symptoms that were 
not related to any specifi c physical condi-
tion but were to be ticked according to 
the interviewer’s judgment. The SCAN 
system had two essential elements: a glos-
sary of defi nitions and CATEGO (a data 
processing computer program). 
4. A questionnaire on the diazepam usage 
pattern was drawn up for this study, 
composed of open questions and ques-
tions with multiple-choice answers in 
two domains: the patient’s habits and 
diffi culties regarding chronic use of the 
medication and the patient’s opinion 
about the prescription and the physician’s 
prescribing behavior. 
Procedure
The patients received letters explaining 
the objectives and procedures of the study and 
recalling them to the PHCC. After they signed 
an informed consent form, the interview was 
carried out. A report on the patient’s condition 
revealing diazepam dependence was discussed 
with the attending physician and attached to 
the respective fi le. The fi rst author of the present 
study (C.S.R), who underwent training on ap-
plying SCAN at a World Health Organization 
accredited center, conducted all the interviews. 
This research protocol was approved by the 
Ethics Committee of the Medical School of 
Universidade Estadual de Campinas.
Data analysis
The data were organized in frequency 
tables with the respective percentages. Means 
and standard deviations were calculated for 
continuous variables. SCAN data were proc-
essed using the CATEGO system.24 
RESULTS
Most of the patients who had been using 
diazepam continuously for 36 months were 
women (85.4%) and white (85.4%). The 
patients’ mean age was 57.6 years (standard 
deviation, SD = 12.5) and only four patients 
were below the age of 40 years; 43.9% were 
married and 70.8% were Catholics. The pa-
tients were from the social strata C (39%), D 
(54%) and E (7%).
The mean duration of diazepam consump-
tion was 10 years (SD = 7.95). The patients be-
gan using diazepam at an average age of 43 years 
(SD = 14) and generally (73.2 %) took a single 
nocturnal dose of 10 mg. Thirty-seven (90.2%) 
out of the 41 patients used some other medica-
tion besides diazepam: mainly antihypertensives, 
antiarrhythmics and antidepressives (26, 8 and 
7 patients, respectively). Ten patients (24.4%) 
used three or more drugs besides diazepam.  
Table 1 demonstrates the percentages of 
affi rmative responses to the items in the ques-
tionnaire on usage patterns. When an attempt 
to stop using the drug was made, at least one 
withdrawal symptom was highlighted. Among 
the withdrawal symptoms remembered by the 
patients when answering the item “Report 
what you felt ……”, the most common ones 
were insomnia (46.3%), agitation (9.7%), 
headaches or pain in the limbs (9.7%) and 
irritability (9.7%). Six of the seven patients 
who reported taking diazepam overdoses had 
needed urgent medical care. Ten of the 30 pa-
tients who tried to stop taking diazepam were 
motivated by their physicians to do so. 
Table 1. Pattern of benzodiazepine usage among patients in public primary health-
care centers
n = 41 %
Signifi cant withdrawal symptoms 36 87.8
Frustrated attempts to stop consumption 30 76.9
If the drug was not supplied, patient would pay for it 17 43.6
Habit of lending the medication to others 17 41.5
Lack of compliance regarding prescription* 16 39.0
Preoccupations about chronic effects of diazepam 13 30.2
“Suggestion” of diazepam use to others 06 15.0
Intake of several pills at the same time 06 14.6
*Negative answer to the question “Have you used diazepam according to your physician’s prescription?” 
Table 2. Reasons for starting to use diazepam and continuing with it, as reported by 
the patients of public primary healthcare centers
n = 41 %
Main reason for starting 
    Nervousness 17 41.4
    Insomnia 15 36.6
    Fear/panic 4 9.8
    Fainting 3 7.3
    Hypertension 2 4.9
Main reason for continuing 
    Insomnia 10 24.4
    Calming effect 9 21.9
    Dependence 5 12.2
    Depression 3 7.3
    Fainting 1 2.4
    Heart problems 1 2.4
    Cramps in the limbs 1 2.4
    Hypertension  1 2.4
    “I don’t know why” 10 24.4
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The reasons reported for beginning and 
continuing to use diazepam can be seen in 
Table 2 (spontaneous answers to the open 
questions: “Why do you think your physician 
prescribed diazepam?” and “Why did you 
continue using diazepam?”). 
The specialty of the prescribing physi-
cian was: general clinician (44.4% of the 
cases), psychiatrist (41.7%), cardiologist 
(5.6%), neurologist (5.6%) and gynecolo-
gist (2.8%). With regard to the guidance 
given by the prescribing physician for the pa-
tient’s health problem, 22.5% of the patients 
Table 3. Schedule for Clinical Assessment in Neuropsychiatry (SCAN) frequencies for 
physical and emotional symptoms among diazepam users
Description of symptoms %
Physical symptoms
    Pain in the arms, legs, joints, hands and feet 
    Problems with sight, hearing and speech 
    Palpitations, heart beating without stopping  
    Dry mouth
    Memory loss
    Dormancy, cramps 
    Short respiration with no physical exercise 
    Hot and cold fl ushes
    Headaches 












    Depressive mood 
    No hope for the future 
    Preoccupation
    Generalized/localized muscular tension
    Lack of energy
    Initial insomnia 
    Satisfactory quality of sleep
    Feelings of psychomotor retardation 
    Unresponsive depression 











Table 4. Frequency of mental disorders according to the International Classifi cation of 








Recurrent depressive disorder (F33) 1 12 31.7
Mental disorders caused by the use of sedatives and hypnotics (F13) 1 11 29.2
Dysthymia (F34.1) 0 10 24.3
Sleep disorder (G47) 0 6 14.6
Generalized anxiety disorder (F41.1) 0 3 7.3
Somatoform disorder (F45) 1 2 7.3
Mental disorder caused by a brain lesion (F06) 0 2 4.8
Depressive episode (F32) 0 2 4.8
Schizoaffective disorder, depressive type (F25.1) 1 0 2.4
Bipolar affective disorder in remission (F31.7) 1 0 2.4
Obsessive-compulsive disorder (F42) 0 1 2.4
Intentional exposure to analgesics, antipyretics and antirheumatics (X60) 0 1 2.4
*More than one diagnostic category was given to some patients.
reported they had received guidelines but 
did not understand them, 55.5% affi rmed 
that they had never received any guidance 
and only 15% (eight patients) remembered 
some information received from the doc-
tor. According to the HAD scale, 64.1% 
of the cases presented anxiety and 69.2% 
presented depression. 
Table 3 shows the ten most common 
physical and emotional symptoms verifi ed by 
SCAN. Table 4 presents a list of the psychiatric 
diagnoses based on the International Classifi -
cation of Diseases, 10th edition (ICD-10), that 
were obtained from SCAN. This only detected 
12 cases of benzodiazepine dependence.   
DISCUSSION
Studies that specifi cally report on ben-
zodiazepine consumption at PHCCs are 
rare.25-27 Our study provided an estimate of the 
diazepam usage pattern as well as the patients’ 
clinical profi le.
Some methodological limitations should 
be taken into consideration. The first of 
these was the lack of a precise instrument 
for evaluating benzodiazepine dependence, 
since the SCAN criterion for benzodiazepine 
dependence has proved to have little sensitiv-
ity. Other studies28,29 have already suggested 
that the operational criteria used in the diag-
nostic assessment of psychoactive substance 
dependence have proved to be useless with 
regard to benzodiazepines. The benzodi-
azepine dependence indicators suggested by 
a Canadian study were: self-identifi cation as a 
dependent, enumeration of multiple stressors 
to justify use, use based on anticipated stress, 
minimization of damage, storage of medica-
tion and failure to stop or diminish use.29 
Our fi ndings reinforce the need for greater 
precision in establishing operational criteria 
for benzodiazepine dependence.
With regard to the patients’ sociodemo-
graphic profi le, it is important to remember 
that our study comprised patients seen at 
PHCCs, within the public heath system. 
There were no individuals belonging to so-
cioeconomic levels A and B. Both Brazilian 
and international studies agree that women 
aged over 40 years and elderly men present 
the highest prevalence of benzodiazepine 
use.2,6,8,17,25-30 However, it should be borne in 
mind that our sample came from a region of 
the city of Campinas in which the residents 
are predominantly in lower middle and poor 
social classes, and are, therefore, public service 
users, and this impedes data generalization.
The overall trend was for individuals to 
use constant doses of benzodiazepine, with no 
progressive increases in dosage. Our fi ndings 
regarding the reasons why the fi rst prescription 
was issued (agitation and insomnia) were in 
accordance with other studies.30-32 
The patients’ clear lack of understand-
ing regarding the physician’s instructions 
may be partly explained by their poor level 
of schooling. In addition to the specifi c 
maintenance prescription treatment, the 
physician ends up simply repeating previ-
ous prescriptions, thereby perpetuating a 
practice that is not always based on formal 
therapeutic criteria. Repeated prescriptions 
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at each visit, together with the patient’s per-
sonality characteristics, may increase the risk 
of benzodiazepine dependence.30-34
In the present study, 25 patients (61%) 
suffered from depression, according to the 
diagnoses produced by SCAN. The frequency 
with which depressive symptoms appear in 
the list of most reported emotional symptoms 
was also noticeable (it is worth clarifying that 
the patients were asked about each symptom 
in the SCAN list). On the other hand, there 
was no spontaneous report of depression 
as the main reason for having started us-
ing benzodiazepine. It is known that many 
patients suffering from depression who are 
seen by general practitioners are given only 
benzodiazepine for anxiety symptoms and 
insomnia, instead of the appropriate treat-
ment for depression. Quality of care in cases 
of depression depends on good communi-
cation between the doctor and the patient, 
but patients who are depressed often have 
diffi culty in discussing their problems with 
doctors. They are also unlikely to be active 
in seeking care and have low expectations of 
what the treatment can provide.31,32
According to our fi ndings, the chronic 
benzodiazepine users at PHCCs did not have 
the required information and consequently 
did not have any preoccupations about the 
appropriateness of their treatment. When 
they did, they were unable to stop taking 
benzodiazepines without presenting with-
drawal-related symptoms. 
There is a need for guidance and fol-
low-up for chronic users of benzodiazepine, 
especially in view of the low cost and ef-
fectiveness of the intervention programs for 
benzodiazepine-dependent patients. One 
very simple and straightforward program 
showed the positive economic implications 
of sending an educational letter to patients, 
aimed at reducing long-term benzodiazepine 
prescribing. After receiving the letter, 31% of 
those patients discussed their benzodiazepine 
usage with their general practitioner and 10% 
had their drug or drug strength changed. 
During the year following this intervention, a 
signifi cant reduction in benzodiazepine usage 
of 17% was observed in relation to baseline; 
5% of the patients did not order any more 
benzodiazepine prescriptions after receiving 
the letter.31 There is also a need to improve 
medical students’ and professionals’ skills 
regarding the detection and management of 
anxiety and depressive disorders.
CONCLUSION
Chronic benzodiazepine users are fre-
quently women over the age of 40 years, 
who began using the medication because of 
nervousness or insomnia. The usage pattern 
highlighted the patients’ lack of prescription 
compliance, frustrated attempts to stop using 
this drug and frequent chronic concomitant 
use of one or more other drugs. SCAN proved 
to be inadequate for detecting benzodiazepine 
dependence syndrome. Most patients (61%) 
presented with depression.  
274
Sao Paulo Med J. 2007;125(5):270-4.
AUTHOR INFORMATION 
Carmen Sylvia Ribeiro, MD, MSc. Psychiatrist, Department 
of Medical Psychiatry, School of Medical Sciences, 
Universidade Estadual de Campinas, Campinas, São 
Paulo, Brazil. 
Renata Cruz Soares Azevedo, MD, PhD. Psychiatrist and 
professor, Department of Medical Psychiatry, School of 
Medical Sciences, Universidade Estadual de Campinas, 
Campinas, São Paulo, Brazil.
Viviane Franco da Silva, MD, MSc. Psychiatrist, Depart-
ment of Medical Psychiatry, School of Medical Sciences, 
Universidade Estadual de Campinas, Campinas, São 
Paulo, Brazil.
Neury José Botega, MD, PhD. Psychiatrist and professor, 
Department of Medical Psychiatry, School of Medical Sci-
ences, Universidade Estadual de Campinas, Campinas, 
São Paulo, Brazil.
Address for correspondence: 
Neury José Botega
Faculdade de Ciências Médicas da Universidade 
Estadual de Campinas (FCM-Unicamp)
Departamento de Psiquiatria
Caixa Postal, 6.111
Campinas (SP) — Brasil — CEP 13081-970 
Tel./Fax. (+55 19) 3788-7206
E-mail: botega@fcm.unicamp.br
Copyright © 2007, Associação Paulista de Medicina
RESUMO
Uso crônico de diazepam em unidades básicas de saúde: perfi l de usuários e padrão de uso
CONTEXTO E OBJETIVO: O uso crônico de benzodiazepínicos é freqüente. O objetivo deste estudo foi 
descrever o padrão de uso e o perfi l dos usuários crônicos de diazepam (uso contínuo por no mínimo 36 
meses) atendidos em unidades básicas de saúde.
TIPO DE ESTUDO E LOCAL: Estudo descritivo, com inquérito e avaliação clínica padronizada, realizado 
em cinco unidades básicas de saúde de Campinas, São Paulo.
MÉTODO: Os livros de controle de dispensa de psicofármacos revelaram 48 pacientes elegíveis, 41 dos 
quais foram avaliados por meio do Schedule for Clinical Assessment in Neuropsychiatry (SCAN), pela 
escala Hospital Anxiety and Depression (HAD) e de um questionário sobre padrão de uso. 
RESULTADOS: A maioria dos usuários era de mulheres (85,4%), com média de idade de 57,6 anos, 
pertencentes aos estratos socioeconômicos C (39%), D (54%) e E (7%). O tempo médio de uso de diazepam 
foi de 10 anos. Havia inobservância em relação à forma aconselhada de se utilizar o diazepam, bem 
como tentativas frustradas de parar a medicação. 55.5% afi rmaram que não receberam orientações de 
seus médicos sobre os efeitos do medicamento. De acordo com o SCAN, 25 pacientes (61%) sofriam de 
depressão; apenas 12 casos de dependência a benzodiazepinas foram detectados por tal instrumento. 
CONCLUSÃO: São necessárias medidas que possam aprimorar a detecção e tratamento de transtornos 
mentais, assim como prevenir a prescrição e uso inadequado de benzodiazepinas. A dependência de 
bezodiazepínicos tem características que a difereciam de outras dependências químicas e não é detectada 
pelo SCAN.
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